HomeAKBLF • OTCMKTS
add
ALK-Abello A/S
Previous close
$21.35
Year range
$17.90 - $27.03
Market cap
31.26B DKK
Avg Volume
17.00
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
Market news
Financials
Income Statement
Revenue
Net income
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.50B | 11.45% |
Operating expense | 749.00M | 15.23% |
Net income | 170.00M | 21.43% |
Net profit margin | 11.34 | 8.93% |
Earnings per share | 0.80 | 14.29% |
EBITDA | 256.75M | 8.45% |
Effective tax rate | 14.14% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 589.00M | 24.26% |
Total assets | 8.25B | 22.60% |
Total liabilities | 2.87B | 26.06% |
Total equity | 5.37B | — |
Shares outstanding | 221.19M | — |
Price to book | 0.88 | — |
Return on assets | 6.85% | — |
Return on capital | 8.68% | — |
Cash Flow
Net change in cash
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 170.00M | 21.43% |
Cash from operations | 453.00M | 38.96% |
Cash from investing | -1.08B | -1,172.94% |
Cash from financing | 654.00M | 1,823.53% |
Net change in cash | 33.00M | -87.64% |
Free cash flow | -747.88M | -713.01% |
About
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe. Wikipedia
Founded
1923
Website
Employees
2,753
